Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2018, Article ID 1543034, 9 pages
https://doi.org/10.1155/2018/1543034
Review Article

Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis

1Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
3Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
4Canadian College of Naturopathic Medicine, Toronto, ON, Canada
5Department of Pharmacy, The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada
6Department of Psychiatry, Ottawa Hospital, Ottawa, ON, Canada

Correspondence should be addressed to Chakrapani Balijepalli; moc.scimonocehtlaehnoisicerp@illapejilab.inaparkahc

Received 28 August 2017; Accepted 11 February 2018; Published 1 April 2018

Academic Editor: Luis San

Copyright © 2018 Chakrapani Balijepalli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. G. Kumperscak, Childhood and Adolescent Schizophrenia and Other Early-Onset Psychoses, Psychiatric Disorders - Trends and Developments, InTech, 2011.
  3. A. Martin, Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook, Lippincott, Wiliams & Wilkins, London, UK, 4th edition, 2007.
  4. I. Halperin Rabinovich, R. Camara Gomez, M. Garcia Mouriz, and D. Ollero Garcia-Agullo, “Grupo de Trabajo de Neuroendocrinologia de la S [Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia],” Endocrinología y Nutrición, vol. 60, no. 6, pp. 308–319, 2013. View at Google Scholar
  5. A. Majumdar and N. S. Mangal, “Hyperprolactinemia,” Journal of Human Reproductive Sciences, vol. 6, no. 3, pp. 168–175, 2013. View at Publisher · View at Google Scholar
  6. S. Melmed, F. F. Casanueva, A. R. Hoffman et al., “Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 2, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. Inder and D. Castle, “Antipsychotic-induced hyperprolactinaemia,” Australian & New Zealand Journal of Psychiatry, vol. 45, no. 10, pp. 830–837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Peuskens, L. Pani, J. Detraux, and M. de Hert, “The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review,” CNS Drugs, vol. 28, no. 5, pp. 421–453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. U. Correll and C. J. Kratochvil, “Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes,” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 47, no. 1, pp. 9–20, 2008. View at Publisher · View at Google Scholar
  10. B. Vitiello, C. Correll, B. van Zwieten-Boot, A. Zuddas, M. Parellada, and C. Arango, “Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns,” European Neuropsychopharmacology, vol. 19, no. 9, pp. 629–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Alessi-Severini, R. G. Biscontri, D. M. Collins, J. Sareen, and M. W. Enns, “Ten years of antipsychotic prescribing to children: A Canadian population-based study,” The Canadian Journal of Psychiatry, vol. 57, no. 1, pp. 52–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. N. Harrison, F. Cluxton-Keller, and D. Gross, “Antipsychotic Medication Prescribing Trends in Children and Adolescents,” Journal of Pediatric Health Care, vol. 26, no. 2, pp. 139–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Madhusoodanan, S. Parida, and C. Jimenez, “Hyperprolactinemia associated with psychotropics—a review,” Journal of Psychopharmacology, vol. 25, no. 4, pp. 281–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Druyts, M. J. Zoratti, K. Toor et al., “Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review,” BMC Pediatrics, vol. 16, no. 1, article no. 181, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Dias, N. J. Welton, A. J. Sutton, D. M. Caldwell, G. Lu, and A. E. Ades, “Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials,” Medical Decision Making, vol. 33, no. 5, pp. 641–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Dias, A. J. Sutton, A. E. Ades, and N. J. Welton, “Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials,” Medical Decision Making, vol. 33, no. 5, pp. 607–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. E. J. Mills, J. P. A. Ioannidis, K. Thorlund, H. J. Schünemann, M. A. Puhan, and G. H. Guyatt, “How to use an article reporting a multiple treatment comparison meta-analysis,” Journal of the American Medical Association, vol. 308, no. 12, pp. 1246–1253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. P. Jansen, R. Fleurence, B. Devine et al., “Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1,” Value in Health, vol. 14, no. 4, pp. 417–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Findling, K. Mckenna, W. R. Earley, J. Stankowski, and S. Pathak, “Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial,” Journal of Child and Adolescent Psychopharmacology, vol. 22, no. 5, pp. 327–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R. L. Findling, A. Robb, M. Nyilas et al., “A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia,” The American Journal of Psychiatry, vol. 165, no. 11, pp. 1432–1441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Haas, A. S. Unis, J. Armenteros, M. D. Copenhaver, J. A. Quiroz, and S. F. Kushner, “A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia,” Journal of Child and Adolescent Psychopharmacology, vol. 19, no. 6, pp. 611–621, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Kryzhanovskaya, S. C. Schulz, C. McDougle et al., “Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 48, no. 1, pp. 60–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Singh, A. Robb, U. Vijapurkar, I. Nuamah, and D. Hough, “A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents,” Biological Psychiatry, vol. 70, no. 12, pp. 1179–1187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Haas, M. Eerdekens, S. Kushner et al., “Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: Double-blind study,” The British Journal of Psychiatry, vol. 194, no. 2, pp. 158–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Lieberman, T. S. Stroup, J. P. McEvoy et al., “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1209–1223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. McEvoy, J. A. Lieberman, D. O. Perkins et al., “Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison,” The American Journal of Psychiatry, vol. 164, no. 7, pp. 1050–1060, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. McEvoy, J. A. Lieberman, T. S. Stroup et al., “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment,” The American Journal of Psychiatry, vol. 163, no. 4, pp. 600–610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Knegtering, P. Baselmans, S. Castelein, F. Bosker, R. Bruggeman, and R. J. Van Den Bosch, “Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels,” The American Journal of Psychiatry, vol. 162, no. 5, pp. 1010–1012, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. I. Melkersson, “Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite,” Journal of Psychopharmacology, vol. 21, no. 8, pp. 529–532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Leucht, A. Cipriani, and L. Spineli, “Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis,” The Lancet, vol. 382, no. 9896, pp. 951–962, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Saito, C. U. Correll, K. Gallelli et al., “A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents,” Journal of Child and Adolescent Psychopharmacology, vol. 14, no. 3, pp. 350–358, 2004. View at Publisher · View at Google Scholar · View at Scopus